Skip to main content

Table 1 Health care resource use by line of therapy and regimen in Italy, Spain, Germany, and Australia

From: Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study

 

Italy

Spain

Germany

Australia

(N = 174)

(N = 202)

(N = 139)

(N = 208)

Characteristic

N a

Inpatient stayb

Outpatient visit

N a

Inpatient stay

Outpatient visit

N a

Inpatient stay

Outpatient visit

N a

Inpatient stay

Outpatient visit

First-line therapyc

149

36 (24)

143 (96)

130

55 (42)

121 (93)

81

61 (75)

56 (69)

184

83 (45)

177 (96)

 Platinum-based comb.

119

28 (24)

116 (98)

107

49 (46)

98 (92)

73

54 (74)

52 (71)

156

75 (48)

150 (96)

 Non-platinum comb.

0

0

0

3

1 (33)

3 (100)

0

0

0

0

0

0

 Single agent

15

2 (13)

13 (87)

9

1 (11)

9 (100)

4

3 (75)

1 (25)

15

4 (27)

14 (93)

 EGFR/ALK TKI

15

6 (40)

14 (93)

11

4 (36)

11 (100)

4

4 (100)

3 (75)

13

4 (31)

13 (100)

Second-line therapyc

89

20 (22)

88 (99)

68 d

30 (44)

64 (94)

37

27 (73)

32 (87)

118

55 (47)

114 (97)

 Platinum-based comb.

12

3 (25)

12 (100)

14

7 (50)

14 (100)

11

9 (82)

8 (73)

21

7 (33)

21 (100)

 Non-platinum comb.

0

0

0

6

4 (67)

6 (100)

2

1 (50)

1 (50)

1

0

1 (100)

 Single agent

45

12 (27)

44 (98)

34

9 (27)

33 (97)

17

11 (65)

16 (94)

71

34 (48)

69 (97)

 EGFR/ALK TKI

32

5 (16)

32 (100)

12

9 (75)

9 (75)

7

6 (86)

7 (100)

25

14 (56)

23 (92)

  1. Data are n (%) unless otherwise noted
  2. aN represents patients with available HCRU data
  3. bAn inpatient stay was defined as one or more nights in a hospital or hospice
  4. cThe systemic therapy categories were defined as follows:
  5. • Platinum-based combination: regimen with two or more anticancer therapies including carboplatin or cisplatin
  6. • Non-platinum combination: regimen with two or more anticancer therapies not including carboplatin or cisplatin (can contain bevacizumab in combination with other non-platinum drug)
  7. • Single agent: regimen of one anticancer drug that was not an EGFR or ALK tyrosine kinase inhibitor (TKI)
  8. • EGFR/ALK TKI: monotherapy with anti-EGFR (erlotinib, gefitinib, afatinib) or anti-ALK agent (crizotinib, ceritinib)
  9. • Other NSCLC anticancer agent: any other agent not included in the prior categories
  10. dIn Spain during second-line therapy, “Other” NSCLC agents were administered to 2 patients, one of whom had an inpatient stay and both of whom had outpatient visits
  11. ALK anaplastic lymphoma kinase, comb. combination, EGFR epidermal growth factor receptor, NSCLC non-small cell lung cancer, TKI tyrosine kinase inhibitor
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us